Revenues for Q2 2025 were reported at $106 million, down from the prior year, driven by a 29% revenue decline in Argentina’s crop protection segment. Crop nutrition revenues fell to $28 million due to ...

CEO Jon Congleton highlighted the company's focus on advancing its pivotal trials for lorundrostat, targeting dysregulated aldosterone in patients with uncontrolled and resistant hypertension. He ...

While Palantir's hare price has enjoyed a massive spike, one lingering concern is the company's ability to sustain this momentum.

Full-year sales reached $26.8 billion, driven by robust performance across HIV, oncology, and liver disease portfolios. HIV sales grew 8% year-over-year to $19.6 billion in 2024, exceeding ...